ICD harm and benefit: risk scores applied to the Swedish ICD-treated LQTS population

Emilia Sundström1, Steen M Jensen2, Ulla-Britt Diamant2

  • 1Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden.

Insights

Implantable cardioverter defibrillators (ICDs) in long QT syndrome (LQTS) patients carry risks. Risk scores struggled to predict appropriate shocks in low-risk LQTS patients, highlighting complex risk stratification challenges.

Area of Science:

  • Cardiology
  • Genetics
  • Medical Devices

Background:

  • Implantable cardioverter defibrillators (ICDs) are crucial for high-risk long QT syndrome (LQTS) patients.
  • However, ICD use in lower-risk patients may lead to harm outweighing benefits.
  • Accurate risk stratification is essential for optimal ICD implantation decisions.

Purpose of the Study:

  • To evaluate the benefit and harm of ICDs in LQTS patients.
  • To assess the efficacy of risk scores and pre-ICD clinical characteristics in predicting ICD outcomes.
  • To analyze appropriate and inappropriate shock incidence rates and complications.

Main Methods:

  • Retrospective study of 109 Swedish LQTS patients from the Swedish ICD and Pacemaker Registry.
  • Utilized medical records for clinical data collection.
  • Assessed pre-ICD risk using two established risk scores and clinical characteristics.

Main Results:

  • 20% of patients received at least one appropriate shock (incidence rate: 4.3 per 100 person-years).
  • Long QTc interval (≥550 ms) and double mutations were associated with appropriate shocks.
  • Risk scores did not reliably identify low-risk patients without prior cardiac arrest, who still experienced appropriate shocks (incidence rate: 3.0 per 100 person-years for inappropriate shocks; 7.6 per 100 person-years for complications).

Conclusions:

  • ICD implantation in LQTS patients requires careful individual risk assessment.
  • Current risk scores demonstrated limited ability to identify low-risk patients for appropriate shocks in the absence of prior cardiac arrest.
  • The complexity of risk stratification underscores the challenges in optimizing ICD use in LQTS.

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
185
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
398
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
138
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
274